within Pharmacolibrary.Drugs.ATC.N;

model N04BC02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 8.333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 0.25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600,            
    Vdp             = 0.012,
    k12             = 8,
    k21             = 8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N04BC02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Pergolide is an ergot-derived dopamine agonist used in the treatment of Parkinson's disease and, historically, the management of hyperprolactinemia and restless legs syndrome. It was withdrawn from the US and European markets due to an increased risk of cardiac valvulopathy but may still be available in some countries for veterinary use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adult human population as published PK data are unavailable; values below are estimates based on similar dopamine agonists and available summaries.</p><h4>References</h4><ol><li><p>Rendle, DI, et al., &amp; Edwards, S (2019). Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction. <i>Domestic animal endocrinology</i> 68 135–141. DOI:<a href=&quot;https://doi.org/10.1016/j.domaniend.2019.01.008&quot;>10.1016/j.domaniend.2019.01.008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31082785/&quot;>https://pubmed.ncbi.nlm.nih.gov/31082785</a></p></li><li><p>Gehring, R, et al., &amp; Apley, M (2010). Single-dose oral pharmacokinetics of pergolide mesylate in healthy adult mares. <i>Veterinary therapeutics : research in applied veterinary medicine</i> 11(1) E1–E8. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20949429/&quot;>https://pubmed.ncbi.nlm.nih.gov/20949429</a></p></li><li><p>Blin, O (2003). The pharmacokinetics of pergolide in Parkinson&#x27;s disease. <i>Current opinion in neurology</i> 16 Suppl 1 S9–S12. DOI:<a href=&quot;https://doi.org/10.1097/00019052-200312001-00003&quot;>10.1097/00019052-200312001-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15180132/&quot;>https://pubmed.ncbi.nlm.nih.gov/15180132</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N04BC02;
